[go: up one dir, main page]

WO2018155435A1 - Granular preparation - Google Patents

Granular preparation Download PDF

Info

Publication number
WO2018155435A1
WO2018155435A1 PCT/JP2018/005990 JP2018005990W WO2018155435A1 WO 2018155435 A1 WO2018155435 A1 WO 2018155435A1 JP 2018005990 W JP2018005990 W JP 2018005990W WO 2018155435 A1 WO2018155435 A1 WO 2018155435A1
Authority
WO
WIPO (PCT)
Prior art keywords
granule
valine
leucine
granule preparation
gelling agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2018/005990
Other languages
French (fr)
Japanese (ja)
Inventor
泰士 谷川
千里 牧野
信豪 二宮
純 小坂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EA Pharma Co Ltd
Original Assignee
EA Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EA Pharma Co Ltd filed Critical EA Pharma Co Ltd
Priority to CN201880003639.1A priority Critical patent/CN109789120A/en
Priority to PH1/2019/500671A priority patent/PH12019500671B1/en
Priority to JP2019501340A priority patent/JP7080215B2/en
Priority to KR1020197007437A priority patent/KR102555664B1/en
Publication of WO2018155435A1 publication Critical patent/WO2018155435A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

  • the present invention relates to a granule preparation. Specifically, the present invention relates to a granule preparation containing isoleucine, leucine and valine.
  • Rebact registered trademark, hereinafter the same
  • Rebact-blended granule contains 4g of active ingredient in 1 packet (4.15g), and is used to improve hypoalbuminemia in patients with decompensated cirrhosis who exhibit hypoalbuminemia despite adequate food intake (Non-Patent Document 1).
  • the rebact-blended granule is a granule preparation containing a large amount of amino acid components, further improvement in the ingestion feeling such as bitterness derived from amino acids and the mouthfeel of the granules is required.
  • the problem to be solved by the present invention is to provide a granule preparation containing isoleucine, leucine and valine with improved dosing feeling.
  • the present invention is as follows.
  • a granule preparation comprising isoleucine, leucine and valine as active ingredients, comprising a gelling agent.
  • the granule preparation according to any one of (1) to (5), comprising isoleucine / leucine / valine 1 / 1.9 to 2.2 / 1.1 to 1.3 in a weight ratio.
  • a method for producing a granule preparation comprising isoleucine, leucine and valine as active ingredients, A production method of adding a gelling agent to granules containing isoleucine, leucine and valine. (10) The production method according to (9), wherein the gelling agent is added as a powder.
  • Example 1 The result in the elution test of the granule formulation of Example 1 is shown.
  • the result in the elution test of the granule formulation of the comparative example 1 is shown.
  • the granule preparation of the present invention contains isoleucine, leucine and valine as active ingredients and contains a gelling agent.
  • isoleucine, leucine and valine used as active ingredients are amino acids known as branched chain amino acids.
  • D-form and L-form may be used, respectively, a mixture of D-form and L-form in any mixing ratio may be used, and DL-form may be used.
  • Each of isoleucine, leucine and valine may be a chemically synthesized product or a fermented product.
  • Japanese Pharmacopoeia (483, 1711 to 1712, pages 1248, respectively)
  • those satisfying the standards described as L-isoleucine, L-leucine and L-valine are preferably used.
  • containing isoleucine, leucine and valine as active ingredients means that, when the granule preparation of the present invention is used as a pharmaceutical, it contains isoleucine, leucine and valine as ingredients that exhibit efficacy effects. means.
  • the efficacy effect of pharmaceuticals containing isoleucine, leucine and valine as active ingredients in Japan, it is the efficacy effect of rebact-containing granule, which is a commercial product.
  • the improvement of hypoalbuminemia in patients with decompensated cirrhosis presenting is known, but the efficacy effect of the granule preparation containing isoleucine, leucine and valine as active ingredients of the present invention is not limited to this efficacy effect.
  • the granule preparation of the present invention can be used as a pharmaceutical granule preparation by containing isoleucine, leucine and valine as active ingredients.
  • the content of isoleucine, leucine and valine is set as appropriate, but it is preferably 80% or more, more preferably 90% or more as the lower limit of the content as mass% with respect to the total amount of the granule preparation. And more preferably 95% or more.
  • the upper limit of the content of isoleucine, leucine and valine is not particularly limited, but the content of isoleucine, leucine and valine is preferably less than 100%, more preferably 99% or less, and 98% Or less, more preferably 97% or less.
  • the content of isoleucine, leucine and valine may be in a range in which respective values described as preferable values as the upper limit value and the lower limit value are combined.
  • the granule preparation of the present invention contains a gelling agent.
  • the gelling agent means a preparation additive that is a base material that gels by containing water.
  • the gelling agent is not particularly limited, and examples thereof include hypromellose, methylcellulose, hydroxypropylcellulose, carboxyvinyl polymer, sodium alginate, carrageenan, xanthan gum, tamarind gum, pectin, locust bean gum, gellan gum, agar and polyethylene oxide. It is done. From the viewpoints of gelation ability and gelation speed, carboxyvinyl polymer and polyethylene oxide are preferable, and polyethylene oxide is more preferable.
  • a gelatinizer may be used by 1 type and may be used as a 2 or more types of mixture.
  • the average molecular weight of the gelling agent is appropriately set depending on the type of gelling agent from the viewpoint of indexes such as gelling ability and gelling speed.
  • the gelling ability can be confirmed, for example, by observing the appearance when the gelling agent is dissolved in water at high and low concentrations.
  • the gelation speed can be confirmed by adding and dissolving the gelling agent in water and stirring the mixture and observing the state of gelation over time.
  • Examples of the measurement concentration for gelation ability include high concentration (10 w / v%) and low concentration (1 w / v%), and examples of the measurement concentration for gelation rate include 10 w / v%.
  • the lower limit of the average molecular weight preferably has an average molecular weight of 150,000 or more, more preferably has an average molecular weight of 500,000 or more, and more preferably has an average molecular weight of 1,000,000 or more. More preferably, it has an average molecular weight of 2 million or more.
  • the upper limit of the average molecular weight of polyethylene oxide is not particularly limited, but the average molecular weight of polyethylene oxide is preferably 10 million or less, and more preferably 5 million or less.
  • the average molecular weight of the polyethylene oxide may be a range in which respective values described as preferable values as the upper limit value and the lower limit value are combined.
  • the average molecular weight of the gelling agent may be a value displayed on the product, but can be measured as the viscosity average molecular weight by measuring the viscosity of the gelling agent solution.
  • the gelling agent contained in the granule preparation of the present invention is preferably present by adding powder.
  • the powder addition of the gelling agent is performed on elementary granules containing isoleucine, leucine and valine.
  • the gelling agent is present on the surface of the granule as a granule preparation.
  • the granule preparation of the present invention is a so-called coated granule (coated granule).
  • coated granule coated granule
  • the elementary granules containing isoleucine, leucine and valine are coated with a coating solution.
  • the gelling agent is contained in the coating liquid.
  • the presence of the gelling agent added in powder form in the granule preparation is not particularly limited, but for example, it is confirmed by evaluating the gelation ability of the powder obtained by separation by sieving etc. be able to. Moreover, it can also confirm that the gelatinizer exists by adding powder by spectroscopic image observation.
  • the content of the gelling agent is appropriately set depending on the type of the gelling agent, but from the viewpoint of gelling ability and gelling speed, it is preferably 0.01 to 5% as mass% with respect to the total amount of the granule preparation. 0.05 to 2% is more preferable, and 0.05 to 1% is still more preferable. The content of the gelling agent may be 0.1% or more within the above range.
  • the granule preparation of the present invention can be produced by adding a gelling agent to granules containing isoleucine, leucine and valine produced by a conventionally known method.
  • isoleucine, leucine and valine may be mixed and ground with solid raw material amino acids such as isoleucine, leucine and valine to adjust the particle size by the method described in Japanese Patent No. 3228288.
  • solid raw material amino acids such as isoleucine, leucine and valine to adjust the particle size by the method described in Japanese Patent No. 3228288.
  • For the mixing and pulverization either a method of pre-mixing isoleucine, leucine and valine and then pulverizing or a method of pulverizing while mixing isoleucine, leucine and valine can be used.
  • the mixing of the solid raw material amino acid is not particularly limited, but, for example, stirring mixing by rotating a container rotating mixer such as a container mixer, an air stirring mixer such as a fluidized bed mixer, a stirring blade and a stirring ribbon
  • a feeder type mixer installed at a raw material supply port such as a machine, a line mixer for mixing in a powder transportation line, or a pulverizer can be used.
  • the solid raw material amino acid pulverization is not particularly limited.
  • impact type (high-speed rotation type) pulverizer such as hammer mill and pin mill
  • tumbler type (medium type) pulverizer such as ball mill
  • fluid type such as jet mill (jet mill) Airflow type
  • pulverizer can be used.
  • granules containing isoleucine, leucine and valine of the present invention it is not particularly limited.
  • a high-speed stirring granulator, a fluidized bed granulator, a planetary mixer, a dry compaction granulator, a crush granulation A machine, an extrusion granulator, a rolling granulator, a spray drying granulator or a coating granulator can be used. It is preferable to produce granules using a high-speed stirring granulator or an extrusion granulator.
  • extrusion granulator Although it does not specifically limit as an extrusion granulator, for example, a pre-extrusion granulator, a disk pelleter granulator, a ring die granulator, a basket granulator, an oscillating granulator, and a cylinder A type granulator etc. are mentioned.
  • the well-known additive which can be used for the pharmaceuticals which satisfy
  • the additive is not particularly limited, and examples include additives known as binders, lubricants, colorants, plasticizers, surfactants, sweeteners, flavoring agents, flavoring agents, and fragrances. , Binders and / or flavoring agents are preferred.
  • An additive may be used by 1 type and may be used as a 2 or more types of mixture.
  • binder examples include, but are not limited to, cellulose derivatives such as methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and hydroxypropylmethylcellulose phthalate, starches such as corn starch and wheat starch, polyvinylpyrrolidone (povidone), polyvinyl alcohol, Examples thereof include synthetic polymers such as acrylic acid polymers and natural polymers such as gum arabic and gelatin.
  • a corrigent For example, a citric acid, tartaric acid, aspartame, saccharin, a saccharin sodium, an erythritol, a xylitol, a mannitol, a stevia etc. are mentioned.
  • Flavoring agents also include additives known as sweeteners. Although it does not specifically limit as a flavoring agent and a fragrance
  • a flavoring agent and / or a flavoring agent is attached to the surface of the granule by a method described in Japanese Patent No. 3405342 for a granule containing isoleucine, leucine and valine.
  • the particle size of the granule to which the flavoring agent and / or the flavoring agent is attached is not particularly limited as long as the fluidized state can be easily maintained at the normal fluidized bed value, but is generally 100 to 2000 ⁇ m, preferably 200. It is about 1700 ⁇ m.
  • the fluidizing device for adhering the flavoring agent and / or the flavoring agent to the granule is not particularly limited.
  • the fluidizing drying device “Flow Dryer” manufactured by Freund Sangyo Co., Ltd. the fluid manufactured by Freund Sangyo Co., Ltd.
  • examples thereof include a layer granulation coating apparatus “Flow coater”, “Gratt GPCG” manufactured by Paulek, Inc., “Malmerizer” manufactured by Dalton Co., Ltd., and “Multiprocessor” manufactured by Kikusui Seisakusho Co., Ltd.
  • a gelling agent is mixed with a granule containing isoleucine, leucine and valine, preferably a granule to which a corrigent and / or a corrigent is attached.
  • a gelling agent it is preferable to add a gelling agent to a granule containing isoleucine, leucine and valine, preferably a granule to which a corrigent and / or a corrigent is attached, and mix.
  • Such a mixing method is not particularly limited as long as it can be mixed substantially uniformly.
  • a general container rotation type mixer eg, V type, double cone type, rotation swing type, etc.
  • container Examples thereof include a method using a mixer such as a fixed mixer (eg, ribbon type, conical screw type, etc.) or an airflow stirring type mixer.
  • a method may be used in which a prescribed amount of each preparation is put into a predetermined container and mixed by a packaging machine or the like.
  • the granule preparation of the present invention comprises a granule to which a gelling agent is added.
  • the granule is a granule prescribed by the Japanese Pharmacopoeia (refer to page 11 for the 17th revision of the Japanese Pharmacopoeia). .)
  • the particle size of the granule preparation is generally 100 to 2000 ⁇ m, preferably about 200 to 1700 ⁇ m.
  • the particle size means the average particle size of the particles, and can be measured by the general test method 3.04 “particle size measurement method” and the second method “sieving method” described in the 17th revision of the Japanese Pharmacopoeia. (Pages 95-97). In addition, it may be measured by the general test method 6.03 “Test method for particle size of the preparation” described in the 17th revision of the Japanese Pharmacopoeia (page 135).
  • the granule preparation of the present invention can be a granule preparation obtained by the method for producing a granule preparation of the present invention.
  • the granule preparation of the present invention has improved feelings of taking such as a bitterness derived from amino acids and a mouthfeel of granules.
  • a method for improving the ingestion feeling of a granule preparation containing isoleucine, leucine and valine as active ingredients by adding a gelling agent in powder form by adding a gelling agent in powder form.
  • the improvement in the feeling of taking include improvement of bitterness derived from amino acids and improvement of the mouthfeel of granule preparations.
  • Example 1 A granular preparation was prepared based on the formulation described in Table 1. To a mixture of L-isoleucine, L-leucine and L-valine, an aqueous solution of povidone (Collidon, 90F), polyvinyl alcohol (partially saponified product), tartaric acid and saccharin sodium hydrate was added, and stirred granulator The granules were granulated, sized and dried to obtain elementary granules. After spreading the fragrance
  • povidone Collidon, 90F
  • polyvinyl alcohol partially saponified product
  • the granules were granulated, sized and dried to obtain elementary granules. After spreading the fragrance
  • Comparative Example 1 A granular preparation was prepared based on the formulation described in Table 1. Elementary granules were obtained in the same manner as in Example 1. After coating with an aqueous solution of povidone (Kollidon, 90F) on the elementary granules, a fragrance was spread and sized to prepare a granule preparation.
  • povidone Kerdon, 90F
  • the granule preparation of Example 1 is a granule preparation that is superior in ease of swallowing, the difficulty of remaining granules, and the bitterness compared to the granule preparation of Comparative Example 1, which is a formulation of Leveract blended granules. I understood that.
  • Example 1 Using the granule preparations prepared in Example 1 and Comparative Example 1, the dissolution was evaluated by the dissolution test by the paddle method using the second dissolution test in the 17th revision of the Japanese Pharmacopoeia (pages 141-145 general test) Method 6.10 “Dissolution Test Method”). The results are shown in FIGS.
  • Example 1 The granule preparation of Example 1 was confirmed to have low elution at the initial stage (5 minutes value) with respect to the granule preparation of Comparative Example 1, but after 15 minutes, both preparations were almost 100% dissolved. It was confirmed to show sex. It was considered that the granule preparation of Example 1 also showed the same medicinal effect as the Levact mixed granule.
  • Examples 2-4 A granule formulation was prepared in the same manner as in Example 1 except that the content of polyethylene oxide (average molecular weight: 5 million) was 0.1%, 1%, or 2% with respect to the total amount of the granule formulation. Prepared.
  • Examples 5-7 A granule preparation was prepared in the same manner as in Example 1 except that polyethylene oxide having an average molecular weight of 500,000, 1 million or 2 million was used.
  • the granule preparation of the present invention has industrial applicability as a pharmaceutical granule preparation because it is considered to have improved dosing properties with respect to the rebact-blended granules of the current preparation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a granular preparation which has an improved feel of ingestion and comprises isoleucine, leucine and valine. The present invention relates to a granular preparation comprising isoleucine, leucine and valine as active component, the granular preparation containing a gelling agent.

Description

顆粒製剤Granule preparation

　本発明は、顆粒製剤に関する。具体的には、本発明は、イソロイシン、ロイシン及びバリンを含む顆粒製剤に関する。 The present invention relates to a granule preparation. Specifically, the present invention relates to a granule preparation containing isoleucine, leucine and valine.

　イソロイシン、ロイシン及びバリンを含む医薬品としては、肝疾患等に有効な治療薬であるリーバクト（登録商標、以下、同じ。）配合顆粒が市販されている。
　リーバクト配合顆粒は、１包（４．１５ｇ）中に４ｇの有効成分を含み、食事摂取量が十分にもかかわらず低アルブミン血症を呈する非代償性肝硬変患者の低アルブミン血症の改善に用いられている（非特許文献１）。 As pharmaceuticals containing isoleucine, leucine and valine, granules containing Rebact (registered trademark, hereinafter the same), which are effective therapeutic agents for liver diseases, are commercially available.
Rebact-blended granule contains 4g of active ingredient in 1 packet (4.15g), and is used to improve hypoalbuminemia in patients with decompensated cirrhosis who exhibit hypoalbuminemia despite adequate food intake (Non-Patent Document 1).

添付文書　分岐鎖アミノ酸製剤　日本薬局方　イソロイシン・ロイシン・バリン顆粒　リーバクト（登録商標）配合顆粒　２０１６年４月改訂（第１７版）Attached document Branched-chain amino acid preparation Japanese Pharmacopoeia Isoleucine / Leucine / Valine Granules React (Registered Trademark) Combination Granules Revised April 2016 (17th Edition)

　リーバクト配合顆粒は、大量のアミノ酸成分を含む顆粒製剤であることから、アミノ酸に由来する苦味や顆粒の口残りといった服用感のさらなる改善が求められている。 Since the rebact-blended granule is a granule preparation containing a large amount of amino acid components, further improvement in the ingestion feeling such as bitterness derived from amino acids and the mouthfeel of the granules is required.

　本発明の解決しようとする課題は、服用感の改善されたイソロイシン、ロイシン及びバリンを含む顆粒製剤を提供することである。 The problem to be solved by the present invention is to provide a granule preparation containing isoleucine, leucine and valine with improved dosing feeling.

　本発明者らは、鋭意検討した結果、イソロイシン、ロイシン及びバリンを含む顆粒製剤において、ゲル化剤を配合することにより、上記課題を解決し得ることを見出し、本発明を完成した。 As a result of intensive studies, the present inventors have found that the above problems can be solved by blending a gelling agent in a granule preparation containing isoleucine, leucine and valine, and completed the present invention.

　すなわち本発明は以下のとおりである。
（１）
　イソロイシン、ロイシン及びバリン有効成分として含む顆粒製剤であって、ゲル化剤を含む、顆粒製剤。
（２）
　ゲル化剤が、カルボキシビニルポリマー又はポリエチレンオキシドである、（１）に記載の顆粒製剤
（３）
　ゲル化剤が、５０万以上の平均分子量を有するポリエチレンオキシドである、（１）または（２）に記載の顆粒製剤。
（４）
　ゲル化剤が粉末添加されている、（１）～（３）のいずれかに記載の顆粒製剤。
（５）
　顆粒製剤全量に対して、ゲル化剤を０．０５～２％含む、（１）～（４）のいずれかに記載の顆粒製剤。
（６）
　イソロイシン／ロイシン／バリン＝１／１．９～２．２／１．１～１．３の重量比で含む、（１）～（５）のいずれかに記載の顆粒製剤。
（７）
　顆粒製剤全量に対して、イソロイシン、ロイシン及びバリンを８０％以上含む、（１）～（６）のいずれかに記載の顆粒製剤。
（８）
　結合剤及び／又は矯味剤をさらに含む、（１）～（７）のいずれかに記載の顆粒製剤。
（９）
　イソロイシン、ロイシン及びバリンを有効成分として含む顆粒製剤の製造方法であって、
　イソロイシン、ロイシン及びバリンを含む顆粒に、ゲル化剤を添加する、製造方法。
（１０）
　ゲル化剤を粉末添加する、（９）に記載の製造方法。 That is, the present invention is as follows.
(1)
A granule preparation comprising isoleucine, leucine and valine as active ingredients, comprising a gelling agent.
(2)
The granule preparation (3) according to (1), wherein the gelling agent is carboxyvinyl polymer or polyethylene oxide.
The granule preparation according to (1) or (2), wherein the gelling agent is polyethylene oxide having an average molecular weight of 500,000 or more.
(4)
The granule preparation according to any one of (1) to (3), wherein a gelling agent is added as a powder.
(5)
The granule preparation according to any one of (1) to (4), comprising 0.05 to 2% of a gelling agent based on the total amount of the granule preparation.
(6)
The granule preparation according to any one of (1) to (5), comprising isoleucine / leucine / valine = 1 / 1.9 to 2.2 / 1.1 to 1.3 in a weight ratio.
(7)
The granule preparation according to any one of (1) to (6), comprising 80% or more of isoleucine, leucine and valine with respect to the total amount of the granule preparation.
(8)
The granule preparation according to any one of (1) to (7), further comprising a binder and / or a corrigent.
(9)
A method for producing a granule preparation comprising isoleucine, leucine and valine as active ingredients,
A production method of adding a gelling agent to granules containing isoleucine, leucine and valine.
(10)
The production method according to (9), wherein the gelling agent is added as a powder.

　本発明によれば、服用感の改善されたイソロイシン、ロイシン及びバリンを含む顆粒製剤を提供することができる。 According to the present invention, it is possible to provide a granule preparation containing isoleucine, leucine and valine with improved ingestion feeling.

実施例１の顆粒製剤の溶出試験における結果を示す。The result in the elution test of the granule formulation of Example 1 is shown. 比較例１の顆粒製剤の溶出試験における結果を示す。The result in the elution test of the granule formulation of the comparative example 1 is shown.

　本発明を、発明を実施するための形態により具体的に説明するが、本発明は、以下の発明を実施するための形態に限定されるものではなく、種々変形して実施することができる。 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will be specifically described with reference to embodiments for carrying out the invention. However, the present invention is not limited to the embodiments for carrying out the following invention, and can be implemented with various modifications.

　本発明の顆粒製剤は、イソロイシン、ロイシン及びバリンを有効成分として含み、ゲル化剤を含む。
　本発明の顆粒製剤において、有効成分として用いられるイソロイシン、ロイシン及びバリンは、分岐鎖アミノ酸として知られるアミノ酸である。
　本発明においては、それぞれ、Ｄ体、Ｌ体を用いてもよく、Ｄ体とＬ体の任意の混合比の混合物を用いてもよく、ＤＬ体を用いてもよい。
　イソロイシン、ロイシン及びバリンは、それぞれ、化学合成品であっても、発酵品であってもよい。
　日本薬局方第１７改正において（それぞれ、４８３、１７１１～１７１２、１２４８頁）、Ｌ－イソロイシン、Ｌ－ロイシン及びＬ－バリンとして記載されている規格を満たすものを用いることが好ましい。 The granule preparation of the present invention contains isoleucine, leucine and valine as active ingredients and contains a gelling agent.
In the granule preparation of the present invention, isoleucine, leucine and valine used as active ingredients are amino acids known as branched chain amino acids.
In the present invention, D-form and L-form may be used, respectively, a mixture of D-form and L-form in any mixing ratio may be used, and DL-form may be used.
Each of isoleucine, leucine and valine may be a chemically synthesized product or a fermented product.
In the 17th revision of the Japanese Pharmacopoeia (483, 1711 to 1712, pages 1248, respectively), those satisfying the standards described as L-isoleucine, L-leucine and L-valine are preferably used.

　本発明において、イソロイシン、ロイシン及びバリンを有効成分として含むとは、本発明の顆粒製剤を医薬品として用いた場合に、効能効果を発揮する成分として、イソロイシン、ロイシン及びバリンを含んでいるということを意味する。
　イソロイシン、ロイシン及びバリンを有効成分として含む医薬品の効能効果としては、日本国においては、市販製品であるリーバクト配合顆粒での効能効果である「食事摂取量が十分にもかかわらず低アルブミン血症を呈する非代償性肝硬変患者の低アルブミン血症の改善」が知られているが、本発明のイソロイシン、ロイシン及びバリンを有効成分として含む顆粒製剤の効能効果としては、かかる効能効果のみに限定されない。
　本発明においては、有効成分として、他の成分を含むことを妨げないが、イソロイシン、ロイシン及びバリンのみを含むことが好ましい。
　本発明の顆粒製剤は、イソロイシン、ロイシン及びバリンを有効成分として含むことにより、医薬用顆粒製剤として用いることができる。 In the present invention, containing isoleucine, leucine and valine as active ingredients means that, when the granule preparation of the present invention is used as a pharmaceutical, it contains isoleucine, leucine and valine as ingredients that exhibit efficacy effects. means.
As for the efficacy effect of pharmaceuticals containing isoleucine, leucine and valine as active ingredients, in Japan, it is the efficacy effect of rebact-containing granule, which is a commercial product. The improvement of hypoalbuminemia in patients with decompensated cirrhosis presenting is known, but the efficacy effect of the granule preparation containing isoleucine, leucine and valine as active ingredients of the present invention is not limited to this efficacy effect.
In the present invention, it is preferable to include only isoleucine, leucine and valine, although it does not prevent other components from being included as active ingredients.
The granule preparation of the present invention can be used as a pharmaceutical granule preparation by containing isoleucine, leucine and valine as active ingredients.

　本発明の顆粒製剤において、イソロイシン、ロイシン及びバリンの含有比は、特に限定されないが、重量比として、イソロイシン／ロイシン／バリン＝１／１．９～２．２／１．１～１．３であることが好ましい。
　イソロイシン、ロイシン及びバリンの含有量は、適宜設定されるが、顆粒製剤全量に対する質量％として、その含有量の下限値として、８０％以上であることが好ましく、９０％以上であることがより好ましく、９５％以上であることがさらに好ましい。
　イソロイシン、ロイシン及びバリンの含有量の上限値としては、特に限定されないが、イソロイシン、ロイシン及びバリンの含有量は、１００％未満であることが好ましく、９９％以下であることがより好ましく、９８％以下であることがさらに好ましく、９７％以下であることがよりさらに好ましい。
　イソロイシン、ロイシン及びバリンの含有量は、上限値及び下限値として好ましい値として記載するそれぞれの値を組み合わせた範囲であってよい。 In the granule preparation of the present invention, the content ratio of isoleucine, leucine and valine is not particularly limited, but as a weight ratio, isoleucine / leucine / valine = 1 / 1.9 to 2.2 / 1.1 to 1.3. Preferably there is.
The content of isoleucine, leucine and valine is set as appropriate, but it is preferably 80% or more, more preferably 90% or more as the lower limit of the content as mass% with respect to the total amount of the granule preparation. And more preferably 95% or more.
The upper limit of the content of isoleucine, leucine and valine is not particularly limited, but the content of isoleucine, leucine and valine is preferably less than 100%, more preferably 99% or less, and 98% Or less, more preferably 97% or less.
The content of isoleucine, leucine and valine may be in a range in which respective values described as preferable values as the upper limit value and the lower limit value are combined.

　本発明の顆粒製剤は、ゲル化剤を含む。
　本発明において、ゲル化剤とは、水を含むことによってゲル化する基材である製剤添加物であることを意味する。
　ゲル化剤としては、特に限定されないが、例えば、ヒプロメロース、メチルセルロース、ヒドロキシプロピルセルロース、カルボキシビニルポリマー、アルギン酸ナトリウム、カラギーナン、キサンタンガム、タマリンドガム、ペクチン、ローカストビーンガム、ジェランガム、寒天及びポリエチレンオキシド等が挙げられる。
　ゲル化能とゲル化速度の観点で、カルボキシビニルポリマー及びポリエチレンオキシドが好ましく、ポリエチレンオキシドがより好ましい。
　ゲル化剤は、１種で用いてもよく、２種以上の混合物として用いてもよい。 The granule preparation of the present invention contains a gelling agent.
In the present invention, the gelling agent means a preparation additive that is a base material that gels by containing water.
The gelling agent is not particularly limited, and examples thereof include hypromellose, methylcellulose, hydroxypropylcellulose, carboxyvinyl polymer, sodium alginate, carrageenan, xanthan gum, tamarind gum, pectin, locust bean gum, gellan gum, agar and polyethylene oxide. It is done.
From the viewpoints of gelation ability and gelation speed, carboxyvinyl polymer and polyethylene oxide are preferable, and polyethylene oxide is more preferable.
A gelatinizer may be used by 1 type and may be used as a 2 or more types of mixture.

　ゲル化剤の平均分子量は、ゲル化能とゲル化速度といった指標の観点から、ゲル化剤の種類により適宜設定される。
　ゲル化能は、例えば、ゲル化剤を高濃度、低濃度で水に溶解した際の外観を観察することにより確認することができる。
　また、ゲル化速度は、ゲル化剤を水へ添加溶解後に撹拌し、経時的にゲル化の状況を観察していくことにより確認することができる。
　ゲル化能の測定濃度としては、例えば高濃度（10w/v%）及び低濃度（1w/v%）が、ゲル化速度の測定濃度としては、例えば10w/v%等が挙げられる。 The average molecular weight of the gelling agent is appropriately set depending on the type of gelling agent from the viewpoint of indexes such as gelling ability and gelling speed.
The gelling ability can be confirmed, for example, by observing the appearance when the gelling agent is dissolved in water at high and low concentrations.
The gelation speed can be confirmed by adding and dissolving the gelling agent in water and stirring the mixture and observing the state of gelation over time.
Examples of the measurement concentration for gelation ability include high concentration (10 w / v%) and low concentration (1 w / v%), and examples of the measurement concentration for gelation rate include 10 w / v%.

　ポリエチレンオキシドにおいては、その平均分子量の下限値として、１５万以上の平均分子量を有することが好ましく、５０万以上の平均分子量を有することがより好ましく、１００万以上の平均分子量を有することがさらに好ましく、２００万以上の平均分子量を有することがよりさらに好ましい。
　ポリエチレンオキシドの平均分子量の上限値としては、特に限定されないが、ポリエチレンオキシドの平均分子量は、１０００万以下であることが好ましく、５００万以下であることがより好ましい。
　ポリエチレンオキシドの平均分子量は、上限値及び下限値として好ましい値として記載するそれぞれの値を組み合わせた範囲であってよい。 In polyethylene oxide, the lower limit of the average molecular weight preferably has an average molecular weight of 150,000 or more, more preferably has an average molecular weight of 500,000 or more, and more preferably has an average molecular weight of 1,000,000 or more. More preferably, it has an average molecular weight of 2 million or more.
The upper limit of the average molecular weight of polyethylene oxide is not particularly limited, but the average molecular weight of polyethylene oxide is preferably 10 million or less, and more preferably 5 million or less.
The average molecular weight of the polyethylene oxide may be a range in which respective values described as preferable values as the upper limit value and the lower limit value are combined.

　本発明において、ゲル化剤の平均分子量は、製品に表示される値であってもよいが、ゲル化剤の溶液の粘度を測定することによって、粘度平均分子量として測定することができる。 In the present invention, the average molecular weight of the gelling agent may be a value displayed on the product, but can be measured as the viscosity average molecular weight by measuring the viscosity of the gelling agent solution.

　本発明の顆粒製剤に含まれるゲル化剤は、粉末添加されて存在していることが好ましい。
　ゲル化剤の粉末添加は、イソロイシン、ロイシン及びバリンを含む素顆粒に対して行われる。素顆粒に対して、ゲル化剤が粉末添加されることにより、顆粒製剤として、顆粒の表面にゲル化剤が粉末添加された状態で存在することとなる。 The gelling agent contained in the granule preparation of the present invention is preferably present by adding powder.
The powder addition of the gelling agent is performed on elementary granules containing isoleucine, leucine and valine. By adding a gelling agent in powder form to the elementary granules, the gelling agent is present on the surface of the granule as a granule preparation.

　本発明の顆粒製剤においてゲル化剤が粉末添加されている場合、顆粒表面にゲル化剤が粉末添加された状態で存在しているので、本発明の顆粒製剤は、いわゆるコーティング顆粒（被覆顆粒）として、顆粒表面にゲル化剤がコーティングされている顆粒製剤とは異なる。
　コーティング顆粒においては、イソロイシン、ロイシン及びバリンを含む素顆粒に対して、コーティング液によりコーティングされる。この場合、ゲル化剤は、コーティング液中に含まれる。
　顆粒製剤において、ゲル化剤が粉末添加されて存在していることは、特に限定されないが、例えば、篩い分け等により分離することにより得られた粉末のゲル化能等を評価することで確認することができる。また、分光画像観察等により、ゲル化剤が粉末添加されて存在していることを確認することもできる。 When the gelling agent is added in powder form in the granule preparation of the present invention, since the gelling agent is present on the granule surface in a powdered state, the granule preparation of the present invention is a so-called coated granule (coated granule). As different from the granule preparation in which the gel surface is coated with a gelling agent.
In the coated granules, the elementary granules containing isoleucine, leucine and valine are coated with a coating solution. In this case, the gelling agent is contained in the coating liquid.
The presence of the gelling agent added in powder form in the granule preparation is not particularly limited, but for example, it is confirmed by evaluating the gelation ability of the powder obtained by separation by sieving etc. be able to. Moreover, it can also confirm that the gelatinizer exists by adding powder by spectroscopic image observation.

　ゲル化剤の含有量は、ゲル化剤の種類により適宜設定されるが、ゲル化能とゲル化速度の観点で、顆粒製剤全量に対する質量％として、０．０１～５％であることが好ましく、０．０５～２％であることがより好ましく、０．０５～１％であることがさらに好ましい。ゲル化剤の含有量は、上記範囲内で、０．１％以上であってもよい。 The content of the gelling agent is appropriately set depending on the type of the gelling agent, but from the viewpoint of gelling ability and gelling speed, it is preferably 0.01 to 5% as mass% with respect to the total amount of the granule preparation. 0.05 to 2% is more preferable, and 0.05 to 1% is still more preferable. The content of the gelling agent may be 0.1% or more within the above range.

　本発明の顆粒製剤は、従来公知の方法によって製した、イソロイシン、ロイシン及びバリンを含む顆粒に、ゲル化剤を添加することにより製造することができる。 The granule preparation of the present invention can be produced by adding a gelling agent to granules containing isoleucine, leucine and valine produced by a conventionally known method.

　本発明において、イソロイシン、ロイシン及びバリンは、特許第３２２８２８８号に記載される方法により、イソロイシン、ロイシン及びバリンである固形原料アミノ酸を混合粉砕して粒度を調整してもよい。
　混合粉砕は、イソロイシン、ロイシン及びバリンを予め混合した後に粉砕する方法、又はイソロイシン、ロイシン及びバリンを混合しながら粉砕する方法のいずれも利用することができる。 In the present invention, isoleucine, leucine and valine may be mixed and ground with solid raw material amino acids such as isoleucine, leucine and valine to adjust the particle size by the method described in Japanese Patent No. 3228288.
For the mixing and pulverization, either a method of pre-mixing isoleucine, leucine and valine and then pulverizing or a method of pulverizing while mixing isoleucine, leucine and valine can be used.

　固形原料アミノ酸の混合においては、特に限定されないが、例えば、コンテナ式混合機等の容器回転型混合機、流動層型混合機等のエアー撹拌型混合機、撹拌羽根及び撹拌リボンの回転による撹拌混合機、粉体輸送ライン中で混合するライン混合機又は粉砕機等の原料供給口に設置されるフィーダー型混合機を利用することができる。 The mixing of the solid raw material amino acid is not particularly limited, but, for example, stirring mixing by rotating a container rotating mixer such as a container mixer, an air stirring mixer such as a fluidized bed mixer, a stirring blade and a stirring ribbon A feeder type mixer installed at a raw material supply port such as a machine, a line mixer for mixing in a powder transportation line, or a pulverizer can be used.

　固形原料アミノ酸の粉砕においては、特に限定されないが、例えば、ハンマーミルやピンミル等の衝撃式（高速回転式）粉砕機、ボールミル等のタンブラー式（媒体式）粉砕機又はジェットミル等の流体式（気流式）粉砕機を利用することができる。 The solid raw material amino acid pulverization is not particularly limited. For example, impact type (high-speed rotation type) pulverizer such as hammer mill and pin mill, tumbler type (medium type) pulverizer such as ball mill, or fluid type such as jet mill (jet mill) Airflow type) pulverizer can be used.

　本発明の、イソロイシン、ロイシン及びバリンを含む顆粒の製造においては、特に限定されないが、例えば、高速攪拌造粒機、流動層造粒機、プラネタリーミキサー、乾式圧扁造粒機、破砕造粒機、押出し造粒機、転動造粒機、噴霧乾燥造粒機又はコーティング造粒機を利用することができる。
　高速攪拌造粒機又は押し出し造粒機を用いて、顆粒を製造することが好ましい。
　押出し造粒機としては、特に限定されないが、例えば、前押し出し式造粒機、ディスクペレッター式造粒機、リングダイ式造粒機、バスケット式造粒機、オシレーティング式造粒機及びシリンダー式造粒機等が挙げられる。 In the production of granules containing isoleucine, leucine and valine of the present invention, it is not particularly limited. For example, a high-speed stirring granulator, a fluidized bed granulator, a planetary mixer, a dry compaction granulator, a crush granulation A machine, an extrusion granulator, a rolling granulator, a spray drying granulator or a coating granulator can be used.
It is preferable to produce granules using a high-speed stirring granulator or an extrusion granulator.
Although it does not specifically limit as an extrusion granulator, For example, a pre-extrusion granulator, a disk pelleter granulator, a ring die granulator, a basket granulator, an oscillating granulator, and a cylinder A type granulator etc. are mentioned.

　顆粒を製造する場合には、日本薬局方又は医薬品添加物規格等の規格を満たしている医薬用として使用できる公知の添加剤を配合することができる。
　添加剤としては、特に限定されないが、例えば、結合剤、滑沢剤、着色剤、可塑剤、界面活性剤、甘味料、矯味剤、矯臭剤及び香料等として知られる添加剤が挙げられ、中でも、結合剤及び／又は矯味剤が好ましい。
　添加剤は、１種で用いてもよく、２種以上の混合物として用いてもよい。 When manufacturing a granule, the well-known additive which can be used for the pharmaceuticals which satisfy | fills specifications, such as a Japanese Pharmacopoeia or a pharmaceutical additive specification, can be mix | blended.
The additive is not particularly limited, and examples include additives known as binders, lubricants, colorants, plasticizers, surfactants, sweeteners, flavoring agents, flavoring agents, and fragrances. , Binders and / or flavoring agents are preferred.
An additive may be used by 1 type and may be used as a 2 or more types of mixture.

　結合剤としては、特に限定されないが、例えば、メチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ヒドロキシプロピルメチルセルロースフタレート等のセルロース誘導体、トウモロコシデンプン、コムギデンプン等のデンプン類、ポリビニルピロリドン（ポビドン）、ポリビニルアルコール、アクリル酸ポリマーなどの合成高分子類及びアラビアゴム、ゼラチン等の天然高分子類等が挙げられる。
　矯味剤としては、特に限定されないが、例えば、クエン酸、酒石酸、アスパルテーム、サッカリン、サッカリンナトリウム、エリスリトール、キシリトール、マンニトール及びステビア等が挙げられる。矯味剤には、甘味料として知られる添加剤も含まれる。
　矯臭剤及び香料としては、特に限定されないが、例えば、メントール、レモンフレーバー、シュガーレス、スィートフレーバー及びストロベリーオイル等が挙げられる。 Examples of the binder include, but are not limited to, cellulose derivatives such as methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and hydroxypropylmethylcellulose phthalate, starches such as corn starch and wheat starch, polyvinylpyrrolidone (povidone), polyvinyl alcohol, Examples thereof include synthetic polymers such as acrylic acid polymers and natural polymers such as gum arabic and gelatin.
Although it does not specifically limit as a corrigent, For example, a citric acid, tartaric acid, aspartame, saccharin, a saccharin sodium, an erythritol, a xylitol, a mannitol, a stevia etc. are mentioned. Flavoring agents also include additives known as sweeteners.
Although it does not specifically limit as a flavoring agent and a fragrance | flavor, For example, menthol, lemon flavor, sugarless, sweet flavor, strawberry oil, etc. are mentioned.

　本発明においては、好適には、イソロイシン、ロイシン及びバリンを含む顆粒に対して、特許第３４０５３４２号に記載される方法により、矯味剤及び／又は矯臭剤が顆粒の表面に付着される。
　矯味剤及び／又は矯臭剤が付着される顆粒の粒度は、通常の流動化層値において容易に流動状態を維持できる限り、特に限定されないが、一般的には１００～２０００μｍであり、好ましくは２００～１７００μｍ程度である。 In the present invention, preferably, a flavoring agent and / or a flavoring agent is attached to the surface of the granule by a method described in Japanese Patent No. 3405342 for a granule containing isoleucine, leucine and valine.
The particle size of the granule to which the flavoring agent and / or the flavoring agent is attached is not particularly limited as long as the fluidized state can be easily maintained at the normal fluidized bed value, but is generally 100 to 2000 μm, preferably 200. It is about 1700 μm.

　矯味剤及び／又は矯臭剤を顆粒に付着させるための流動化装置としては、特に限定されないが、例えば、フロイント産業（株）製の流動乾燥装置「フロードライヤー」、フロイント産業（株）製の流動層造粒コーティング装置「フローコーター」、（株）パウレック製の「グラットＧＰＣＧ」、（株）ダルトン製「マルメライザー」及び（株）菊水製作所製「マルチプロセッサー」等が挙げられる。 The fluidizing device for adhering the flavoring agent and / or the flavoring agent to the granule is not particularly limited. For example, the fluidizing drying device “Flow Dryer” manufactured by Freund Sangyo Co., Ltd., the fluid manufactured by Freund Sangyo Co., Ltd. Examples thereof include a layer granulation coating apparatus “Flow coater”, “Gratt GPCG” manufactured by Paulek, Inc., “Malmerizer” manufactured by Dalton Co., Ltd., and “Multiprocessor” manufactured by Kikusui Seisakusho Co., Ltd.

　本発明においては、イソロイシン、ロイシン及びバリンを含む顆粒、好ましくは、矯味剤及び／又は矯臭剤が付着されている顆粒に、ゲル化剤を混合する。
　本発明においては、イソロイシン、ロイシン及びバリンを含む顆粒、好ましくは、矯味剤及び／又は矯臭剤が付着されている顆粒に、ゲル化剤を粉末添加して混合することが好適である。
　かかる混合方法としては、略均一に混合せしめ得る方法であれば特に限定されないが、例えば、一般的な容器回転型混合機（例、V型、二重円錐型、回転揺動型等）、容器固定型混合機（例、リボン型、円錐スクリュー型等）又は気流攪拌型混合機等の混合機を用いた方法が挙げられる。
　分包機等により各々の製剤の規定量を定められた容器に投入し混合する方法を利用してもよい。 In the present invention, a gelling agent is mixed with a granule containing isoleucine, leucine and valine, preferably a granule to which a corrigent and / or a corrigent is attached.
In the present invention, it is preferable to add a gelling agent to a granule containing isoleucine, leucine and valine, preferably a granule to which a corrigent and / or a corrigent is attached, and mix.
Such a mixing method is not particularly limited as long as it can be mixed substantially uniformly. For example, a general container rotation type mixer (eg, V type, double cone type, rotation swing type, etc.), container Examples thereof include a method using a mixer such as a fixed mixer (eg, ribbon type, conical screw type, etc.) or an airflow stirring type mixer.
A method may be used in which a prescribed amount of each preparation is put into a predetermined container and mixed by a packaging machine or the like.

　イソロイシン、ロイシン及びバリンを含む顆粒に、ゲル化剤を粉末添加して混合することにより、ゲル化剤が粉末添加された状態で存在する顆粒製剤が得られる。
　本発明の顆粒製剤は、ゲル化剤を添加した顆粒からなるが、かかる顆粒は、日本薬局方に規定されている顆粒剤である（日本薬局方第１７改正であれば１１頁を参照のこと。）。
　本発明において、顆粒製剤の粒度は、一般的には１００～２０００μｍであり、好ましくは２００～１７００μｍ程度である。 By adding and mixing a gelling agent into granules containing isoleucine, leucine and valine, a granule preparation in which the gelling agent is added in powder is obtained.
The granule preparation of the present invention comprises a granule to which a gelling agent is added. The granule is a granule prescribed by the Japanese Pharmacopoeia (refer to page 11 for the 17th revision of the Japanese Pharmacopoeia). .)
In the present invention, the particle size of the granule preparation is generally 100 to 2000 μm, preferably about 200 to 1700 μm.

　本発明において、粒度とは、粒子の平均粒子径を意味するが、日本薬局方第１７改正記載の一般試験法３．０４「粒度測定法」第２法「ふるい分け法」により測定することができる（９５～９７頁）。なお、日本薬局方第１７改正記載の一般試験法６．０３「製剤の粒度の試験法」により測定してもよい（１３５頁）。 In the present invention, the particle size means the average particle size of the particles, and can be measured by the general test method 3.04 “particle size measurement method” and the second method “sieving method” described in the 17th revision of the Japanese Pharmacopoeia. (Pages 95-97). In addition, it may be measured by the general test method 6.03 “Test method for particle size of the preparation” described in the 17th revision of the Japanese Pharmacopoeia (page 135).

　本発明の顆粒製剤は、本発明の顆粒製剤の製造方法により得られる顆粒製剤であり得る。
　本発明の顆粒製剤は、アミノ酸に由来する苦味や顆粒の口残りといった服用感が改善されている。 The granule preparation of the present invention can be a granule preparation obtained by the method for producing a granule preparation of the present invention.
The granule preparation of the present invention has improved feelings of taking such as a bitterness derived from amino acids and a mouthfeel of granules.

　本発明においては、ゲル化剤を粉末添加しておくことによる、イソロイシン、ロイシン及びバリンを有効成分として含む顆粒製剤の服用感の改善方法を提供する。服用感の改善としては、アミノ酸に由来する苦味の改善や、顆粒製剤の口残り改善等が挙げられる。 In the present invention, there is provided a method for improving the ingestion feeling of a granule preparation containing isoleucine, leucine and valine as active ingredients by adding a gelling agent in powder form. Examples of the improvement in the feeling of taking include improvement of bitterness derived from amino acids and improvement of the mouthfeel of granule preparations.

　以下、本発明を実施例に基づいて具体的に説明するが、本発明は何らこれに限定されない。当業者は、本発明の意義を逸脱することなく様々な態様に本発明を変更することができ、かかる変更も本発明の範囲に含まれる。 Hereinafter, the present invention will be specifically described based on examples, but the present invention is not limited thereto. Those skilled in the art can change the present invention into various modes without departing from the meaning of the present invention, and such changes are also included in the scope of the present invention.

実施例１
　表１に記載する処方に基づいて、顆粒製剤を調製した。
　Ｌ－イソロイシン、Ｌ－ロイシン及びＬ－バリンの混合物に対して、ポビドン（コリドン、９０Ｆ）、ポリビニルアルコール（部分けん化物）、酒石酸及びサッカリンナトリウム水和物の水溶液を添加して、撹拌造粒機により造粒し、整粒、乾燥することにより素顆粒を得た。
　素顆粒に対して、香料を展延し、整粒した後、ポリエチレンオキシド（平均分子量：５００万）を粉末添加して、顆粒製剤を調製した。 Example 1
A granular preparation was prepared based on the formulation described in Table 1.
To a mixture of L-isoleucine, L-leucine and L-valine, an aqueous solution of povidone (Collidon, 90F), polyvinyl alcohol (partially saponified product), tartaric acid and saccharin sodium hydrate was added, and stirred granulator The granules were granulated, sized and dried to obtain elementary granules.
After spreading the fragrance | flavor with respect to the elementary granule and adjusting the size, polyethylene oxide (average molecular weight: 5 million) was added as a powder to prepare a granule preparation.

比較例１
　表１に記載する処方に基づいて、顆粒製剤を調製した。
　実施例１と同様にして素顆粒を得た。
　素顆粒に対して、ポビドン（コリドン、９０Ｆ）の水溶液を用いてコーティングした後、香料を展延して、整粒することにより、顆粒製剤を調製した。 Comparative Example 1
A granular preparation was prepared based on the formulation described in Table 1.
Elementary granules were obtained in the same manner as in Example 1.
After coating with an aqueous solution of povidone (Kollidon, 90F) on the elementary granules, a fragrance was spread and sized to prepare a granule preparation.

Figure JPOXMLDOC01-appb-T000001
Figure JPOXMLDOC01-appb-T000001

　実施例１及び比較例１で調製した顆粒製剤を用いて、飲込み易さ、顆粒の残りにくさ、苦味の弱さを指標として、官能評価を行った。（ｎ＝９）
　飲込み易さについては、服用した際の両顆粒製剤を比較して、飲込み易い方を選択した。
　顆粒の残りにくさについては、服用した際の両顆粒製剤を比較して、口の中に残りにくい方を選択した。
　苦味の弱さについては、両顆粒製剤を比較して、苦味の弱い方を選択した。
　結果を表２に示す。 Using the granule preparations prepared in Example 1 and Comparative Example 1, sensory evaluation was performed using the ease of swallowing, difficulty of remaining granules, and weak bitterness as indicators. (N = 9)
For ease of swallowing, the two granule preparations when taken were compared and the one that was easy to swallow was selected.
Regarding the difficulty of remaining granules, the two granule preparations when taken were compared and the one that was less likely to remain in the mouth was selected.
About the weak bitterness, both granule preparations were compared and the weak bitterness was selected.
The results are shown in Table 2.

Figure JPOXMLDOC01-appb-T000002
Figure JPOXMLDOC01-appb-T000002

　実施例１の顆粒製剤は、リーバクト配合顆粒の処方である比較例１の顆粒製剤に対して、飲込み易さ、顆粒の残りにくさ、苦味について優れることから、服用感に優れる顆粒製剤であることが分かった。 The granule preparation of Example 1 is a granule preparation that is superior in ease of swallowing, the difficulty of remaining granules, and the bitterness compared to the granule preparation of Comparative Example 1, which is a formulation of Leveract blended granules. I understood that.

　実施例１及び比較例１で調製した顆粒製剤を用いて、日本薬局方第１７改正における溶出試験第２液を用いたパドル法による溶出試験により、溶出性を評価した（１４１～１４５頁　一般試験法６．１０「溶出試験法」）。
　結果を図１及び図２に示す。 Using the granule preparations prepared in Example 1 and Comparative Example 1, the dissolution was evaluated by the dissolution test by the paddle method using the second dissolution test in the 17th revision of the Japanese Pharmacopoeia (pages 141-145 general test) Method 6.10 “Dissolution Test Method”).
The results are shown in FIGS.

　実施例１の顆粒製剤は、比較例１の顆粒製剤に対して、初期（５分値）での溶出性が低いことが確認されたが、１５分以降においては両製剤ともにほぼ100%の溶出性を示すことが確認された。実施例１の顆粒製剤も、リーバクト配合顆粒同様の薬効を示すと考えられた。 The granule preparation of Example 1 was confirmed to have low elution at the initial stage (5 minutes value) with respect to the granule preparation of Comparative Example 1, but after 15 minutes, both preparations were almost 100% dissolved. It was confirmed to show sex. It was considered that the granule preparation of Example 1 also showed the same medicinal effect as the Levact mixed granule.

実施例２～４
　ポリエチレンオキシド（平均分子量：５００万）の含量が、顆粒製剤全量に対して、０．１％、１％又は２％となるようにしたこと以外は、実施例１と同様にして、顆粒製剤を調製した。 Examples 2-4
A granule formulation was prepared in the same manner as in Example 1 except that the content of polyethylene oxide (average molecular weight: 5 million) was 0.1%, 1%, or 2% with respect to the total amount of the granule formulation. Prepared.

実施例５～７
　平均分子量が５０万、１００万又は２００万であるポリエチレンオキシドを用いる以外は、実施例１と同様にして、顆粒製剤を調製した。 Examples 5-7
A granule preparation was prepared in the same manner as in Example 1 except that polyethylene oxide having an average molecular weight of 500,000, 1 million or 2 million was used.

　実施例１～７で調製した顆粒製剤を用いて、異物感、苦味、嚥下し易さを指標として、官能評価を行った。（ｎ＝１０）
　各指標に対して、感じない：１点、あまり感じない：２点、まあまあ感じる：３点、感じる：４点として点数付し、平均値を求めた。結果を表３に示す。 Using the granule preparations prepared in Examples 1 to 7, sensory evaluation was performed by using the foreign body feeling, bitterness, and ease of swallowing as indices. (N = 10)
For each index, I did not feel: 1 point, I did not feel much: 2 points, I felt so good: 3 points, I felt: I scored 4 points, and calculated the average value. The results are shown in Table 3.

Figure JPOXMLDOC01-appb-T000003
Figure JPOXMLDOC01-appb-T000003

　本発明の顆粒製剤は、現行製剤のリーバクト配合顆粒に対して改良された服用性を有すると考えられるため、医薬用顆粒製剤として、産業上の利用可能性を有する。 The granule preparation of the present invention has industrial applicability as a pharmaceutical granule preparation because it is considered to have improved dosing properties with respect to the rebact-blended granules of the current preparation.

Claims (10)

　イソロイシン、ロイシン及びバリン有効成分として含む顆粒製剤であって、ゲル化剤を含む、顆粒製剤。 Granule preparation containing isoleucine, leucine and valine as active ingredients and containing a gelling agent. 　ゲル化剤が、カルボキシビニルポリマー又はポリエチレンオキシドである、請求項１に記載の顆粒製剤。 The granule preparation according to claim 1, wherein the gelling agent is carboxyvinyl polymer or polyethylene oxide. 　ゲル化剤が、５０万以上の平均分子量を有するポリエチレンオキシドである、請求項１または２に記載の顆粒製剤。 The granule preparation according to claim 1 or 2, wherein the gelling agent is polyethylene oxide having an average molecular weight of 500,000 or more. 　ゲル化剤が粉末添加されている、請求項１～３のいずれか１項に記載の顆粒製剤。 The granule preparation according to any one of claims 1 to 3, wherein a gelling agent is added as a powder. 　顆粒製剤全量に対して、ゲル化剤を０．０５～２％含む、請求項１～４のいずれか１項に記載の顆粒製剤。 The granule preparation according to any one of claims 1 to 4, comprising 0.05 to 2% of a gelling agent based on the total amount of the granule preparation. 　イソロイシン／ロイシン／バリン＝１／１．９～２．２／１．１～１．３の重量比で含む、請求項１～５のいずれか１項に記載の顆粒製剤。 6. The granule preparation according to any one of claims 1 to 5, comprising isoleucine / leucine / valine = 1 / 1.9 to 2.2 / 1.1 to 1.3 in a weight ratio. 　顆粒製剤全量に対して、イソロイシン、ロイシン及びバリンを８０％以上含む、請求項１～６のいずれか１項に記載の顆粒製剤。 The granule preparation according to any one of claims 1 to 6, comprising 80% or more of isoleucine, leucine and valine with respect to the total amount of the granule preparation. 　結合剤及び／又は矯味剤をさらに含む、請求項１～７のいずれか１項に記載の顆粒製剤。 The granule preparation according to any one of claims 1 to 7, further comprising a binder and / or a corrigent. 　イソロイシン、ロイシン及びバリンを有効成分として含む顆粒製剤の製造方法であって、
　イソロイシン、ロイシン及びバリンを含む顆粒に、ゲル化剤を添加する、製造方法。 A method for producing a granule preparation comprising isoleucine, leucine and valine as active ingredients,
A production method of adding a gelling agent to granules containing isoleucine, leucine and valine. 　ゲル化剤を粉末添加する、請求項９に記載の製造方法。 The production method according to claim 9, wherein the gelling agent is added in powder form.
PCT/JP2018/005990 2017-02-21 2018-02-20 Granular preparation Ceased WO2018155435A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201880003639.1A CN109789120A (en) 2017-02-21 2018-02-20 Granular preparation
PH1/2019/500671A PH12019500671B1 (en) 2017-02-21 2018-02-20 Granular preparation
JP2019501340A JP7080215B2 (en) 2017-02-21 2018-02-20 Granule preparation
KR1020197007437A KR102555664B1 (en) 2017-02-21 2018-02-20 granule formulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017-030368 2017-02-21
JP2017030368 2017-02-21

Publications (1)

Publication Number Publication Date
WO2018155435A1 true WO2018155435A1 (en) 2018-08-30

Family

ID=63253165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/005990 Ceased WO2018155435A1 (en) 2017-02-21 2018-02-20 Granular preparation

Country Status (6)

Country Link
JP (1) JP7080215B2 (en)
KR (1) KR102555664B1 (en)
CN (1) CN109789120A (en)
PH (1) PH12019500671B1 (en)
SG (1) SG10202109130WA (en)
WO (1) WO2018155435A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526887A (en) * 1997-12-20 2001-12-25 ジェネンコア インターナショナル インコーポレーテッド Matrix granules
WO2009017193A1 (en) * 2007-07-31 2009-02-05 Ajinomoto Co., Inc. Amino-acid-containing medicinal granular preparation highly easy to take
JP2011093879A (en) * 2009-10-02 2011-05-12 Ajinomoto Co Inc Granule containing branched-chain amino acid, and method for producing the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1040191A1 (en) * 1998-07-31 2002-05-31 大塚制药株式会社 Pharmaceutical composition having improved taste
JP3211824B1 (en) * 2000-10-26 2001-09-25 味の素株式会社 Pharmaceutical granule preparation containing branched-chain amino acid and method for producing the same
JP3981134B2 (en) * 2003-10-29 2007-09-26 塩野義製薬株式会社 Method for producing coated preparation with improved unpleasant taste
PE20141034A1 (en) * 2008-03-11 2014-09-10 Takeda Pharmaceutical SOLID ORAL DISINTEGRATION PREPARATION
JP5360368B2 (en) * 2008-09-05 2013-12-04 味の素株式会社 Amino acid preparation for oral use with improved dosage
JP2013014590A (en) * 2012-08-02 2013-01-24 Otsuka Pharmaceut Co Ltd Atrophy inhibitor of alimentary canal and kidney

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526887A (en) * 1997-12-20 2001-12-25 ジェネンコア インターナショナル インコーポレーテッド Matrix granules
WO2009017193A1 (en) * 2007-07-31 2009-02-05 Ajinomoto Co., Inc. Amino-acid-containing medicinal granular preparation highly easy to take
JP2011093879A (en) * 2009-10-02 2011-05-12 Ajinomoto Co Inc Granule containing branched-chain amino acid, and method for producing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Hand book of Pharmaceutical Excipients", INTERNATIONAL PHARMACEUTICAL EXCIPIENTS COUNCIL, 2007, pages 835 - 837 *

Also Published As

Publication number Publication date
KR20190117469A (en) 2019-10-16
CN109789120A (en) 2019-05-21
JPWO2018155435A1 (en) 2019-12-12
PH12019500671A1 (en) 2019-07-24
PH12019500671B1 (en) 2024-02-02
SG10202109130WA (en) 2021-09-29
KR102555664B1 (en) 2023-07-18
JP7080215B2 (en) 2022-06-03

Similar Documents

Publication Publication Date Title
WO2009142255A1 (en) Cellulose powder having excellent segregation preventive effect, and compositions thereof
CN103610680B (en) A kind of CEFUROXIME AXETIL composition and method of making the same
JP6998210B2 (en) Particle composition for easy-to-take solid preparation and easy-to-take solid preparation containing the particle composition
SG184951A1 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
CN115803020A (en) Orally disintegrating tablet containing milobarin besylate
WO2012133658A1 (en) Bottled beverage comprising cap containing dietary supplement and bottle filled with dispersion medium for dietary supplement
JP2016174616A (en) Disintegrable composition, and easily disintegrable compression molding
EP2983650A1 (en) Oral pharmaceutical composition comprising taste-masked n-acetylcysteine
JP5582033B2 (en) Oral preparation containing branched chain amino acids
JP5515943B2 (en) Granules containing branched chain amino acids and method for producing the same
JPWO2019202968A1 (en) Easy-to-take granules and their manufacturing method
JP5275815B2 (en) Orally disintegrating tablets and bitterness-suppressing preparations containing risperidone
JP7080215B2 (en) Granule preparation
JP6384068B2 (en) Amino acid-containing granules and method for producing the same
JP6104038B2 (en) Composite composition of crystalline cellulose
JP2008162955A (en) Valine-containing high density granular agent
JPWO2014017507A1 (en) Solid preparation
JP2013136537A (en) Tablet and method of producing the same
HK40003126A (en) Granular preparation
JP2005008640A (en) Composition suppressing unpleasant taste of ingredient having unpleasant taste
JP2007008872A (en) Method for producing granulated particles, granulated particles thereof, and solid preparation
ES2384577T3 (en) Coated Granular Formulations
JP2008189634A (en) Method for producing intraorally quickly disintegrable tablet
JP2023160929A (en) High-dispersibility dextrin powder
JP6051059B2 (en) Etodolac-containing particles and etodolac-containing solid preparations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18756731

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 20197007437

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019501340

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18756731

Country of ref document: EP

Kind code of ref document: A1